Spots Global Cancer Trial Database for ovarian
Every month we try and update this database with for ovarian cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| CT-2106 for the Second Line Treatment of Ovarian Cancer | NCT00291837 | Ovarian Cancer | CT-2106 | 18 Years - | CTI BioPharma | |
| Itraconazole in Advanced Ovarian Cancer | NCT05591560 | Ovarian Carcino... | Itraconazole ca... Placebo | 18 Years - 65 Years | Tanta University | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Open Label Immunotherapy Trial for Ovarian Cancer | NCT03556566 | Ovarian Cancer | Tableted vaccin... | 18 Years - 65 Years | Immunitor LLC | |
| Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00484666 | Ovarian Cancer | 18 Years - | Carilion Clinic | ||
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | NCT02605083 | Cancer | eFT508 | 18 Years - | Effector Therapeutics | |
| A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | NCT00683241 | Ovarian Cancer Peritoneal Canc... | DCVac-L | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | NCT04503265 | Advanced Malign... Breast Cancer Ovarian Cancer Homologous Reco... Prostate Cancer Pancreatic Canc... | AMXI-5001:Dose ... AMXI-5001:Dose ... | 18 Years - | AtlasMedx, Incorporated | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Blood Test for Ovarian Cancer Associated Antibodies (CAAb) | NCT00327925 | Ovarian Cancer | Find Cancer Ass... | 18 Years - | Lab Discoveries Ltd. | |
| Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | NCT00477282 | Ovarian Cancer | Karenitecin Topotecan | 18 Years - | BioNumerik Pharmaceuticals, Inc. | |
| Safety and Efficacy Study of Glufosfamide in Ovarian Cancer | NCT00442598 | Ovarian Cancer | Glufosfamide | 18 Years - | Eleison Pharmaceuticals LLC. | |
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | NCT01616303 | Ovarian Neoplas... | Carboplatin Paclitaxel oregovomab | 18 Years - 75 Years | Quest PharmaTech Inc. | |
| Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | NCT03154281 | Breast Cancer Ovarian Cancer | niraparib everolimus | 18 Years - | Avera McKennan Hospital & University Health Center | |
| Blood Test for Ovarian Cancer Associated Antibodies (CAAb) | NCT00327925 | Ovarian Cancer | Find Cancer Ass... | 18 Years - | Lab Discoveries Ltd. | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | NCT01519869 | Primary Periton... Ovarian Carcino... Fallopian Tube ... | neoadjuvant che... | 18 Years - | University of Kentucky | |
| A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | NCT03395080 | Endometrial Can... Uterine Cancer Ovarian Cancer Carcinosarcoma | Paclitaxel 300mg DKN-01 600mg DKN-01 | 18 Years - | Leap Therapeutics, Inc. | |
| Clinical Study of WT2725 in Patients With Advanced Malignancies | NCT01621542 | Cancer | WT2725 | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | NCT01952249 | Primary Periton... | Demcizumab Taxol | 21 Years - 90 Years | Mereo BioPharma | |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | NCT00722592 | Ovarian Cancer | Vintafolide pegylated lipos... EC20 | 18 Years - | Endocyte | |
| Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines | NCT03622931 | Ovarian Cancer | Standard chemot... Romiplostim Placebos | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer | NCT00929162 | Patients With A... | ZD4054 Zibotent... Paclitaxel Carboplatin Placebo | 18 Years - | AstraZeneca | |
| Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer | NCT01017809 | Ovarian Cancer | Aprepitant | 18 Years - | NYU Langone Health | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers | NCT00608452 | Lung Cancer Ovarian Cancer Breast Cancer Hodgkin's Disea... Neuroblastoma | Symptom Assessm... | - | Memorial Sloan Kettering Cancer Center | |
| Fermented Wheat Germ Extract in Women With Ovarian Cancer | NCT02411565 | Ovarian Cancer | Fermented Wheat... Placebo Standard of Car... Quality of Life... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | NCT03836352 | Ovarian Cancer Hepatocellular ... Non-small Cell ... Bladder Cancer Microsatellite ... | DPX-Survivac Cyclophosphamid... Pembrolizumab | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) | NCT01170650 | Ovarian Cancer | EC145 Pegylated Lipos... placebo EC20 | 18 Years - | Endocyte | |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | NCT01219777 | Ovarian Cancer Primary Periton... Fallopian Tube ... | carboplatin Bevacizumab Paclitaxel | 18 Years - 90 Years | Ohio State University Comprehensive Cancer Center | |
| Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms | NCT00160472 | Ovarian Neoplas... | removal of ovar... | 18 Years - | Tripler Army Medical Center | |
| Accelerating Gastrointestinal Recovery | NCT01704651 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Alvimopan Placebo | 18 Years - | Mayo Clinic | |
| Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | NCT01220154 | Ovarian Cancer Fallopian Tube ... Primary Periton... No Prior Chemot... | Paclitaxel Carboplatin Bevacizumab | 18 Years - 90 Years | Ohio State University Comprehensive Cancer Center | |
| Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer. | NCT02910622 | Breast Cancer Ovarian Cancer | Chimio-oncogram... | 18 Years - | University Hospital, Limoges | |
| Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer | NCT03754569 | Epithelial Ovar... | Peritoneal biop... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | NCT00035100 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | epothilone b | 18 Years - | Novartis | |
| A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | NCT00082212 | Ovarian Cancer | Cetuximab | 18 Years - | Eli Lilly and Company | |
| Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer | NCT00888810 | Cancer Ovarian Relapse Chemotherapy | TOPOTECAN LAPATINIB | 18 Years - | Centre Francois Baclesse | |
| Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | NCT00928642 | Ovarian Cancer Primary Periton... | imatinib mesyla... Gemcitabine Int... | 18 Years - | Henry M. Jackson Foundation for the Advancement of Military Medicine | |
| A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | NCT00683241 | Ovarian Cancer Peritoneal Canc... | DCVac-L | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | NCT00319748 | Breast Cancer Ovarian Cancer Endometrial Can... Cervical Cancer | 852A | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca | NCT00787488 | Ovarian Cancer | Hyperthermia | 18 Years - 72 Years | Duke University | |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | NCT04902872 | Solid Tumor, Ad... Epithelial Ovar... Small Cell Lung... Breast Cancer Colorectal Canc... Pancreas Cancer Appendix Cancer Non-small Cell ... Gastric Cancer Esophagus Cance... Urothelial Carc... Sarcoma | CBX-12 | 18 Years - | Cybrexa Therapeutics | |
| Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin | NCT05514028 | Ovarian Cancer Ovarian Cyst Be... Borderline Ovar... | Salivary sample... | 18 Years - | ZIWIG | |
| Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors | NCT01440504 | Ovarian Cancer | culture ex vivo... | 18 Years - | Centre Francois Baclesse | |
| Role of Surgery in Advanced Ovarian Cancer | NCT03980028 | Ovarian Cancer | 18 Years - | Institut Claudius Regaud | ||
| Use of Regorafenib in Recurrent Epithelial Ovarian Cancer | NCT02736305 | Ovarian Neoplas... | Regorafenib | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide | NCT00132522 | Ovarian Cancer Colorectal Canc... Carcinoma, Non-... Prostate Cancer | EMD 273066 | 18 Years - | EMD Serono | |
| Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | NCT00408967 | Ovarian Cancer | Tucotuzumab cel... | 18 Years - | EMD Serono | |
| A Phase I Study of ECO-4601 in Patients With Advanced Cancer | NCT00338026 | Tumors Glioma Colorectal Canc... Lung Cancer Breast Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer | ECO-4601 | 18 Years - | Thallion Pharmaceuticals | |
| Intra-peritoneal Chemotherapy in Ovarian Cancer | NCT02861872 | Ovarian Neoplas... Immune Toleranc... Neoplasms Effects of Chem... | 18 Years - 70 Years | Radboud University Medical Center | ||
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | NCT00722592 | Ovarian Cancer | Vintafolide pegylated lipos... EC20 | 18 Years - | Endocyte | |
| A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer | NCT00816764 | Carcinoma Ovarian Cancer Ovarian Disease... Ovarian Neoplas... | AGS-8M4 | 18 Years - | Astellas Pharma Inc | |
| Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients | NCT02470299 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Ketorolac Placebo | 18 Years - | New Mexico Cancer Care Alliance | |
| Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors | NCT01440504 | Ovarian Cancer | culture ex vivo... | 18 Years - | Centre Francois Baclesse | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Role of Surgery in Advanced Ovarian Cancer | NCT03980028 | Ovarian Cancer | 18 Years - | Institut Claudius Regaud | ||
| Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | NCT00972205 | Cervical Ovarian Lung Breast Renal | paclitaxel CBT-1(Registere... Tc 99m sestamib... | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Macroscopic Deciduosis in Pregnancy is Finally a Common Entity | NCT03357783 | Deciduitis; Com... | Macroscopic dec... | 18 Years - 50 Years | Hôpital NOVO | |
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | NCT02605083 | Cancer | eFT508 | 18 Years - | Effector Therapeutics | |
| Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | NCT01078662 | Ovarian Breast Prostate Pancreatic Advanced Tumour... | olaparib | 18 Years - 130 Years | AstraZeneca | |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | NCT04332653 | Any Advanced So... Triple Negative... Non Small Cell ... Small Cell Lung... Microsatellite ... Pancreatic Canc... Ovarian Cancer | NT-I7 pembrolizumab (... | 18 Years - | NeoImmuneTech | |
| Ovarian Tissue Freezing For Fertility Preservation | NCT00902720 | Malignancy Fertility | Tissue sample s... | 18 Years - 41 Years | Oregon Health and Science University | |
| Intra-peritoneal Chemotherapy in Ovarian Cancer | NCT02861872 | Ovarian Neoplas... Immune Toleranc... Neoplasms Effects of Chem... | 18 Years - 70 Years | Radboud University Medical Center | ||
| Blood Test for Ovarian Cancer Associated Antibodies (CAAb) | NCT00327925 | Ovarian Cancer | Find Cancer Ass... | 18 Years - | Lab Discoveries Ltd. | |
| Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | NCT00928642 | Ovarian Cancer Primary Periton... | imatinib mesyla... Gemcitabine Int... | 18 Years - | Henry M. Jackson Foundation for the Advancement of Military Medicine | |
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03170960 | Urothelial Carc... Renal Cell Carc... Non-Small Cell ... Castration-resi... Triple Negative... Ovarian Cancer Endometrial Can... Hepatocellular ... Gastric Cancer Gastroesophagea... Colorectal Canc... Head and Neck C... Differentiated ... Lower Esophagea... | cabozantinib atezolizumab cabozantinib cabozantinib | 18 Years - | Exelixis | |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | NCT04681248 | Esophageal Neop... Adenocarcinoma ... GastroEsophagea... Squamous Cell C... Gastric Adenoca... Endometrial Can... Uterine Cancer Ovarian Cancer Carcinosarcoma Gastric Cancer | DKN-01 | 18 Years - | Leap Therapeutics, Inc. | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors | NCT01440504 | Ovarian Cancer | culture ex vivo... | 18 Years - | Centre Francois Baclesse | |
| Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | NCT00129727 | Ovarian Cancer | Paclitaxel Carboplatin Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | NCT01033292 | Ovarian Cancer | BSI-201 | 18 Years - | Sanofi | |
| Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | NCT01104675 | Ovarian Cancer Fallopian Cance... Peritoneal Canc... | ENMD-2076 | 18 Years - | CASI Pharmaceuticals, Inc. | |
| EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide | NCT00132522 | Ovarian Cancer Colorectal Canc... Carcinoma, Non-... Prostate Cancer | EMD 273066 | 18 Years - | EMD Serono | |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | NCT01033123 | Ovarian Cancer | BSI-201 | 18 Years - | Sanofi | |
| A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | NCT01016054 | Carcinoma Ovarian Cancer Ovarian Disease... Ovarian Neoplas... | AGS-8M4 Pegylated lipos... gemcitabine carboplatin | 18 Years - | Astellas Pharma Inc | |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors | NCT02743637 | Advanced Malign... Advanced Solid ... Neoplasm Metastasis | SDX-7320 | 21 Years - 85 Years | SynDevRx, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
